Dossier
biotech firms
Coverage of biotech firms in the Nexus archive.
Chinaplace1AI-driven drug-design firmstopic1United Statesplace1HSBCorganization1Linda Shuperson1pharmaceutical companiesorganization1European Unionorganization1gene-edited cropstopic1New Genomic Techniquestopic1small-scale farmerstopic1Agnès Ricrochperson1AgroParisTechorganization1Pennsylvania State Universityorganization1
- China AI drug-design deals swell as US scrutiny mounts
China's AI-driven drug-design firms are expanding globally through cross-border dealmaking, with out-licensing deals to major pharmaceutical companies reaching $75 billion in the first five months of 2026, up from zero before 2020. This growth occurs despite increasing US scrutiny of Chinese biotech firms.
- EU welcomes back gene-edited crops, worrying small-scale farmers
The EU has approved the broader use of gene-edited crops using new genomic techniques (NGTs), aiming to enhance resistance to drought and disease amid climate change. However, small-scale farmers express concerns that the high cost and corporate control of these seeds by biotech firms may exacerbate inequality.